149

Octreotide LAR Preparation

Part A

Prescriber Criteria: Consultant Endocrinology & Diabetes
Consultant Oncologist
Consultant Palliative Care

Outpatient and Inpatient use:

1. Malignant Diseases
2. Pituitary Adenomas

Patients with:

- Pituitary adenomas/carcinomas secreting growth hormone (usually until radiotherapy has time to take effect)
- Carcinoid syndrome
- Vasoactive intestinal peptide tumours (VIPomas)
- Insulinomas
- Other hormonally active endocrine neoplasia that are shown to produce a significant response to subcutaneous octreotide such as thyrotropin secreting pituitary adenomas.

Duration of Approval:
1 year

Part B

Prescriber Criteria: Consultant Gastroenterologist
Consultant Surgeon

Outpatient and Inpatient use:

1. Cardiac Arrythmias
2. Chronic Heart Failure
3. Coronary Artery Disease

Patients with gastrointestinal angiodysplasia where endoscopic intervention cannot be undertaken or has proven to be futile.

Duration of Approval:
2 years